News|Articles|September 28, 2026 (Updated: September 29, 2026)

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Listen
0:00 / 0:00

Key Takeaways

  • Zilurgisertib targets constitutively active ALK2 signaling, inhibiting wild-type and ACVR1 R206H variant activity, differentiating it mechanistically from palovarotene and adult-only IV garetosmab.
  • In PROGRESS (n=63), mean total new HO volume change at week 24 favored zilurgisertib (−3.2 cm³) versus placebo (+24.6 cm³), with a Hodges-Lehmann treatment difference of −15.8 cm³.
SHOW MORE

The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.

The FDA has approved zilurgisertib (Atebrioz; Mirum Pharmaceuticals, Incyte Therapeutics), a once-daily oral activin receptor-like kinase 2 (ALK2) inhibitor, to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), according to news releases from the FDA and Mirum Pharmaceuticals.1,2

For pharmacists, the approval brings a third treatment option for an ultra-rare disease, along with a label that carries clinically relevant drug interactions, including a recommendation to avoid concomitant use with metformin.1-3

FOP is a genetic disease caused by a mutation in the activin A receptor type 1 (ACVR1) gene. It causes muscle, tendons, and ligaments to gradually turn into bone, leading to limited movement, deformities, severe disability, and early death. It affects approximately 300 people in the US and 900 worldwide.1,2

A Third Option With a Different Profile

Patients with FOP have constitutively active ALK2 signaling that drives HO; zilurgisertib inhibits both wild-type ALK2 and the pathogenic R206H variant. It joins palovarotene (Sohonos; Ipsen), an oral agent whose dose increases at the time of a flare-up, and garetosmab-grts (Pasatru; Regeneron), an intravenous infusion given every 4 weeks and approved for adults.3-5

"The choice among these 3 medications for a patient with FOP should be dictated by risk/benefit considerations as well as patient characteristics and preferences," said Robert Pignolo, MD, PhD, Robert and Arlene Kogod Professor of Geriatric Medicine at the Mayo Clinic College of Medicine and lead investigator for the PROGRESS study, in an interview with Pharmacy Times. "Considering efficacy among the 3 drugs, garetosmab and zilurgisertib are very effective at preventing heterotopic ossification. Between these 2 medications, zilurgisertib has fewer potentially concerning adverse effects."

Pignolo noted that age eligibility also differs. "Zilurgisertib can be prescribed for children aged 12 and above, while garetosmab is not approved for individuals aged less than 18 years," he said. "Palovarotene can be prescribed for girls aged 8 years and above and boys aged 10 years and above but comes with about a 30% risk of premature growth-plate closure."

PROGRESS Trial Results

Approval was based on cohort 1 of the phase 2 PROGRESS trial (NCT05090891). The trial randomly assigned 63 patients (28 adults and 35 pediatric patients aged 12 years and older) to zilurgisertib 100 mg or placebo once daily for 24 weeks, followed by an open-label extension. The median age was 16 years. At week 24, the mean change in total new HO volume was −3.2 cm³ with zilurgisertib versus +24.6 cm³ with placebo, a Hodges-Lehmann estimated treatment difference of −15.8 cm³ (95% CI, −32.1 to −6.0).1,3

The trial's primary end point, the proportion of patients who developed new HO lesions, favored zilurgisertib numerically (3.1% vs 16.7%; P = .0986) but did not reach statistical significance. According to Mirum and Incyte, no new HO lesions were observed through week 48 among the 61 patients with available scans, including those who crossed over from placebo.1,2,6

Dosing and Interaction Considerations

The recommended dose is 100 mg (four 25-mg tablets) once daily with or without food. Tablets may be swallowed whole or crushed and mixed with 60 mL of water, orange juice, applesauce, or plain yogurt, then taken immediately. Patients should not take zilurgisertib with grapefruit, pomelo, or juices containing them.3

Zilurgisertib is a CYP3A4 substrate. The label calls for reducing the dose to 50 mg once daily with a strong CYP3A4 inhibitor and avoiding strong or moderate CYP3A4 inducers; rifampin, a prescription antibiotic and strong CYP3A4 inducer, decreased zilurgisertib’s area under the curve by 79%. Zilurgisertib also inhibits MATE1 and MATE2-K, so concomitant use with substrates such as metformin should be avoided. If unavoidable, clinicians should monitor for adverse reactions and consider reducing the substrate dose.3

Pignolo explained that metformin "relies heavily on renal transport proteins to be filtered out of the blood and excreted into urine.

"Zilurgisertib acts as an inhibitor of both MATE1 and MATE2-K, so when zilurgisertib blocks these transporters, it restricts the kidneys' ability to eliminate metformin, effectively increasing metformin levels in the blood and increasing the risk of severe metformin-associated toxicities such as lactic acidosis, hypoglycemia, and gastrointestinal distress," he said.

"Pharmacists play a major role in the decision-making process to assure proper identification of patient eligibility and to confirm no contraindications such as drug-drug interactions," Pignolo highlighted.

Safety and Counseling Points

Zilurgisertib is contraindicated in pregnancy. Pregnancy should be ruled out before initiation, and females of reproductive potential should use effective contraception during treatment and for 1 week after the final dose. Breastfeeding is not recommended during treatment and for at least 1 week afterward. 3

Adverse reactions reported more often with zilurgisertib than placebo included:1-3

  • headache (22% vs 16%);
  • arthralgia (22% vs 10%);
  • upper respiratory tract infection (22% vs 10%);
  • epistaxis (13% vs 0%); and
  • nausea (13% vs 3%).

Patients receiving zilurgisertib also had mean increases in serum iron, hemoglobin, and transferrin saturation. These remained within the normal range and were not associated with signs of iron overload through week 100. According to the companies, no adverse events led to discontinuation or dose reduction during the placebo-controlled period.2,3

Zilurgisertib is expected to be available in the US in October through the Mirum Access Plus patient support program, with eligible patients paying as little as $0 per month. Studies in children aged 2 to younger than 12 years are ongoing.2

REFERENCES
1. FDA approves third treatment for fibrodysplasia ossificans progressiva. News release. FDA. Released September 25, 2026. Accessed September 28, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
2. Mirum Pharmaceuticals and Incyte announce U.S. FDA approval of Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva. News release. Mirum Pharmaceuticals, Inc. Released September 25, 2026. Accessed September 28, 2026. https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-U-S--FDA-Approval-of-Atebrioz-zilurgisertib-for-Adult-and-Pediatric-Patients-with-Fibrodysplasia-Ossificans-Progressiva/default.aspx
3. Atebrioz (zilurgisertib) tablets, for oral use. Prescribing information. Mirum Pharmaceuticals, Inc.; revised September 2026. Accessed September 28, 2026. https://files.mirumpharma.com/atebrioz/Atebrioz-USPI-MedGuide.pdf
4. FDA approves first treatment for fibrodysplasia ossificans progressiva. News release. FDA. Released August 17, 2023. Accessed September 28, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva
5. FDA approves second treatment for fibrodysplasia ossificans progressiva. News release. FDA. Released August 19, 2026. Accessed September 28, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva
6. Mirum Pharmaceuticals and Incyte announce positive pivotal phase 2 results from PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva. News release. Mirum Pharmaceuticals, Inc. Released June 14, 2026. Accessed September 28, 2026. https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-Positive-Pivotal-Phase-2-Results-from-PROGRESS-Study-of-Zilurgisertib-in-Fibrodysplasia-Ossificans-Progressiva/default.aspx

Related to this article